Per Lindell

CEO (part time) at Stealth Biotech startup in ophthalmology

Bethesda, United States


Biotechnology Management Consultant

Domain experience

Relevant Total Experience: 30 years

Seniority Level: Senior

Sector Experience: 

Communication Services Consumer Discretionary Consumer Staples Energy Financials FinTech Health Care Industrials Information Technology Materials Real Estate Utilities


Skilled in: Corporate Development, Due Diligence, Legal, Portfolio Services & Add-on M&A, Private Equity & Growth Capital, Sell-side M&A

Languages: German, English, Swedish

Work Experience

Novadigm Consulting Group

Managing Director



- Now

Providing a broad set of services to pharmaceutical and biotechnology companies, including drug design, pre-clinical and clinical development, biologics manufacturing, business development and corporate development (deal scouting, due diligence, execution and M&A), new product launches, strategic planning and financing (VC and IPO). Member of the Umbrex consultant network. Uniquely broad and deep research and business experience. Managed AAV and adeno virus gene therapy and RNA interference therapeutics programs, including discovery (target selection, constructs design and vectors selection), pre-clinical development (program design, vendor selection etc), IND filings, clinical trial design and management, manufacturing (set up and managed pilot and large scale clinical supply manufacturing), as well as business development and M&A. Deep experiencing in biologics manufacturing.





- Now

Umbrex is a selective, global community of top-tier management consultants.

Stealth Biotech startup in ophthalmology

CEO (part time)



- Now

Stealth startup biotechnology company developing drugs for retinal disease with very long duration of action.

Alumni Ventures

AV Expert



- Now

Provide expert advice to biopharmaceutical companies

IBM Global Business Services

Practice Leader in the Pharmaceutical Industry Management Consulting Practice



- 31/1/2011

Marketing, selling and executing management consulting services to Big Pharma clients, focusing on business development, strategic planning and portfolio management.

Independent Management Consultant

Independent Biotechnology Management Consultant



- 31/1/2010

Provided management consulting services to biotechnology companies in business development, strategic planning, clinical development strategies and technology strategies. Consultant COO to public biotech companies in peptide therapeutics. Therapeutic areas included gastrointestinal, oncology, rheumatoid arthritis and autoimmunity, obesity and pain. Modalities included small molecules, peptides, antibodies, siRNA and antisense drugs.

Easton Associates




- 31/1/2009

Managed Easton Associates marketing activities in parallel with an independent management consulting practice. Easton Associates is a biopharmaceutical management consulting firm founded from the former Wilkerson Group.

Genta Inc

Vice President Corporate Development



- 31/1/2007

Managed all corporate development activities for large public antisense company with lead product filed for market approval. Included both in- and out-licensing, acquisition and merger opportunities.

Metaphore Pharmaceuticals

Vice President Corporate Development



- 31/1/2005

Managed all corporate development activates for well funded biotechnology company with a superoxide dismutase mimetics platform which enhances cells management of free radicals. Indications included pain (lead indication in phase 2), inflammation, rheumatoid arthritis, autoimmunity, CNS and respiratory. Also managed CMC activities. Deep involvement with financing activities and IPO preparation.

Avalon Pharmaceuticals

Vice President Business Development



- 31/1/2004

Managed all business development activities for a well funded genomics drug discovery company in oncology. Included large Big Pharma partnership and several mid sized discovery partnerships. Also involved in technology strategy and drug development.


Massachusetts Institute of Technology



- 31/1/1992

KTH Royal Institute of Technology



- 31/1/1981




- 31/1/1978